Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

Annals of Neurology

Volumn 66, Issue 4, 2009, Pages 513-520

  Trojano, Maria ^a   Pellegrini, F ^b   Paolicelli, D ^a   Fuiani, A ^a   Zimatore, G B ^a   Tortorella, C ^a   Simone, I L ^a   Patti, F ^c   Ghezzi, A ^d   Zipoli, V ^e   Rossi, P ^f   Pozzilli, C ^g   Salemi, G ^h   Lugaresi, A ⁱ   Bergamaschi, R ^j   Millefiorini, E ^k   Clerico, M ^l   Lus, G ^m   Vianello, M ⁿ   Avolio, C ^o   Cavalla, P ^l   Lepore, V ^b   Livrea, P ^a   Comi, G ^f   Amato, M P ^e   Di Monte, E ^p   Iaffaldano, P ^p   Direnzo, V ^p   D'Onghia, M ^p   Lo Fermo, S ^p   Messina, S ^p   D'Amico, E ^p   Rizzo, A ^p   Zaffaroni, M ^p   Portaccio, E ^p   Martinelli, V ^p   Prosperini, L ^p   Onesti, E ^p   Aridon, P ^p   D'Amelio, M ^p   Ragonese, P ^p   De Luca, Giovanna ^p   Farina, D ^p   Di Tommaso, V ^p   Tavazzi, E ^p   Bargiggia, V ^p   Crivelli, P ^p   Cortese, A ^p   Di Rezze, S ^p   Durastanti, V ^p   Alfieri, G ^p   Rosellini, I ^p   Modesto, M ^p   Notariello, M ^p   Tortorella, P ^p   more..

^a UNIVERSITY OF BARI   (Italy)

^b Consorzio Mario Negri Sud ^*  (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Hospital of Gallarate   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ UNIVERSITY OF CHIETI   (Italy)

^j C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l UNIVERSITY OF TURIN   (Italy)

^m SECOND UNIVERSITY OF NAPLES   (Italy)

ⁿ CA FONCELLO HOSPITAL   (Italy)

^o UNIVERSITY OF FOGGIA   (Italy)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; ARTICLE; COHORT ANALYSIS; DISABILITY; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

EID: 70449375406     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21757     Document Type: Article

References (38)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993;43:655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294. (Pubitemid 26100751)
3. PRISMS (Prevention of Relapses and Disability by Interferonb-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferonb-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
4. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-306. (Pubitemid 46676729)
5. Trapp BD, Peterson J, Ransohoff RM, et al.. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285. (Pubitemid 28065253)
6. Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-2212.
7. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112(Pt 6):1419-1428.
8. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-134. (Pubitemid 23087038)
9. Kurtzke JF, Beebe GW, Nagler B, et al. Studies on the natural history of multiple sclerosis. 8. Early prognostic features of the later course of the illness. J Chronic Dis 1977;30:819-830.
10. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121(Pt 3):495-503.
11. Tintoré M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-972. (Pubitemid 44454586)
12. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
13. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582. (Pubitemid 32488815)
14. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249. (Pubitemid 44563835)
15. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-684. (Pubitemid 43739821)
16. Kappos L, Freedman MS, Polman CH, et al.; for the BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397.
17. Mechati S, Peyro-St-Paul H. iMed: a new electronic database for monitoring patients with multiple sclerosis. Mult Scler 2001;7:S31.
18. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231. (Pubitemid 13158528)
19. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
20. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
21. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
22. Yanovitzky I, Zanutto E, Hornik R. Estimating causal effects of public health education campaigns using propensity score methodology. Eval Prog Plan 2005;28:209-220. (Pubitemid 40393579)
23. Lin DY, Psaty BM, Krommal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998;54:948-963.
24. The PRISMS (Prevention of Relapses and Disability by Interferon-b-1a Subcutaneously in Multiple Sclerosis) Study Group, and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferonb-1a in relapsing MS. Neurology 2001;56:1628-1636.
25. D'Agostino RB, Jr., D'Agostino RB, Sr. Estimating treatment effects using observational data. JAMA 2007;297:314-316.
26. Noseworthy JH. How much can we learn from long-term extension trials in multiple sclerosis? Neurology 2006;67:930-931.
27. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70. (Pubitemid 32053209)
28. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003;60:1157-1162. (Pubitemid 36418778)
29. Schwid S, Bever CT, Jr. The cost of delaying treatment in multiple sclerosis: what is lost is not regained. Neurology 2001;56:1620.
30. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
31. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-1504.
32. Trojano M, Liguori M, Zimatore GB, et al. Age-related disability in multiple sclerosis. Ann Neurol 2002;51:475-480.
33. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006;129:595-605. (Pubitemid 43278222)
34. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized studies. Stat Med 2007;26:20-36.
35. Normand SLT, Sykora K, Li P, et al. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005;330:1021-1023.
36. Trojano M. Is it time to recognize the use of observational data to estimate treatment effectiveness in multiple sclerosis? Neurology 2007;69:1478-1479.
37. Kern LM, Powe NR, Levine MA, et al. Association between screening for osteoporosis and the incidence of hip fracture. Ann Intern Med 2005;142:173-181. (Pubitemid 40189109)
38. Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg 2007;134:1128-1135.